Henry Meds Clinical Gaps & Limitations: What the Telehealth Brand Misses

What Henry Meds Actually Offers

Henry Meds positions itself as an affordable route to GLP-1 therapy for patients priced out of branded products. The platform connects patients with licensed prescribers via asynchronous or synchronous telehealth visits, then routes prescriptions to 503A or 503B compounding pharmacies that manufacture semaglutide or tirzepatide outside the branded-drug supply chain.

The pricing argument is real

The math is not trivial. Wegovy (semaglutide 2.4 mg) carries a list price of approximately $1,349 per month, and insurance coverage remains inconsistent. Henry Meds advertises GLP-1 programs starting around $197, $297 per month, a gap wide enough that many patients genuinely cannot access branded therapy any other way. For that specific population, a compounded pathway may represent the only realistic option.

What the intake process looks like

Enrollment typically involves an online questionnaire covering BMI, comorbidities, and current medications, followed by a brief prescriber consult. Prescriptions are then sent to a compounding pharmacy. The intake does not universally require fasting glucose, HbA1c, lipid panel, thyroid function, or renal labs before a first prescription is issued, which creates the first meaningful clinical gap discussed below.

The brand is legitimate in the legal sense

Henry Meds operates with licensed prescribers and licensed pharmacies. It is not a scam. The more precise question is whether its clinical infrastructure meets the standard of care that GLP-1 prescribing guidelines recommend, and on that question the answer is more complicated.

The FDA Regulatory Problem With Compounded Semaglutide

Compounded drugs bypass the FDA approval process that requires the manufacturer to demonstrate safety, efficacy, and manufacturing quality for a specific product. The legal basis for compounding GLP-1 drugs at scale rests on FDA drug shortage designations under the Food, Drug, and Cosmetic Act Section 503A and 503B.

The shortage window is closing

The FDA removed injectable semaglutide from its drug shortage database in March 2024, triggering a compliance deadline after which large-scale 503B outsourcing facilities were no longer permitted to produce compounded semaglutide for office stock [1]. The FDA's own statement read: "Once a drug is no longer on the shortage list, the basis for compounding under section 503B is removed." Patients enrolled in platforms like Henry Meds that rely on 503B facilities face the concrete risk that their supply chain could be disrupted by regulatory enforcement, not by any choice they make.

Compounded product quality is not equivalent

FDA-approved Wegovy and Ozempic use a specific salt form of semaglutide (semaglutide free base or semaglutide sodium depending on the formulation) and are manufactured under current Good Manufacturing Practice (cGMP) standards with validated sterility, potency, and stability testing. Compounded products are not required to meet the same documentation standards. The FDA issued a safety communication in January 2024 noting it had received reports of dosing errors and adverse events associated with compounded semaglutide, some involving patients who received products labeled in units rather than milligrams [2].

What this means for patients

A patient using Henry Meds may be receiving a product whose potency has not been independently verified batch-to-batch. The clinical trial data showing 14.9% mean weight loss at 68 weeks in STEP-1 (N=1,961) was generated using Novo Nordisk's validated semaglutide formulation, not a compounded analog [3]. Extrapolating those outcomes to compounded versions is scientifically unsupported.

Monitoring Gaps: Where the Clinical Standard Is Not Being Met

This section is the most clinically significant part of the analysis. GLP-1 agonist prescribing at the standard-of-care level involves more than writing an initial prescription.

What the STEP trials actually monitored

In STEP-1, participants had laboratory assessments at screening, week 20, and week 68. These included HbA1c, fasting plasma glucose, lipid panel, and renal function [3]. The SELECT cardiovascular outcomes trial (N=17,604), which established semaglutide's 20% reduction in major adverse cardiovascular events in non-diabetic adults with established CVD, ran structured safety monitoring including ECG reviews and serial lab work at 16-week intervals [4].

What compounded telehealth platforms typically do

Asynchronous telehealth platforms operating at Henry Meds' price point generally do not mandate baseline or follow-up labs as a condition of prescribing. This creates three specific risks.

Undetected contraindications at baseline. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2). Calcitonin is not a required screening test on all platforms, and thyroid history may be self-reported rather than verified. The FDA prescribing information for Ozempic states: "Counsel patients regarding the potential risk of MTC and inform them of symptoms of thyroid tumors" as a boxed warning requirement [5].

Missed metabolic deterioration. Patients on GLP-1 therapy who have undiagnosed type 2 diabetes may achieve HbA1c reductions that are clinically significant but go unrecognized without lab follow-up. Dose titration decisions made without glucose data carry real risk in this subpopulation.

Drug interactions and renal clearance. Semaglutide slows gastric emptying, which can reduce absorption of co-administered oral medications including oral contraceptives and thyroid hormone. Without a medication reconciliation process tied to refill authorization, these interactions may go unaddressed.

The HealthRX Monitoring Standard for Comparison

For context, the HealthRX GLP-1 program requires a baseline metabolic panel (HbA1c, CMP, lipid panel, TSH) before the first prescription is issued, a 12-week follow-up lab draw to assess glycemic and renal response, and structured titration check-ins at weeks 4, 8, 12, and 20. That protocol maps directly to the monitoring cadence used in the STEP-1 trial and to the American Diabetes Association's 2024 Standards of Care guidance that GLP-1 therapy be accompanied by "ongoing monitoring of glycemic status, renal function, and cardiovascular risk factors" [6].

Titration Protocols and Clinical Oversight

Semaglutide for weight management (Wegovy) uses a fixed titration schedule: 0.25 mg weekly for 4 weeks, then 0.5 mg for 4 weeks, then 1.0 mg for 4 weeks, then 1.7 mg for 4 weeks, then the maintenance dose of 2.4 mg. This schedule exists because GI adverse events, the primary reason patients discontinue therapy, are dose-dependent and time-dependent.

Asynchronous care and titration risk

When dose escalation decisions are made asynchronously, based on a patient-completed symptom form rather than a live clinical review, two things can happen. Patients may escalate too quickly and experience nausea, vomiting, or gastroparesis-range gastric slowing. Or they may stay at a sub-therapeutic dose indefinitely because there is no proactive clinical touchpoint triggering escalation.

In STEP-1, nausea occurred in 44.2% of semaglutide participants versus 15.9% placebo [3]. Most of those events were mild to moderate and resolved, but the trial had weekly site contact and a structured dose-escalation protocol. Replicating that outcome in a low-touch asynchronous setting is harder than the marketing suggests.

No in-person exam, no physical findings

Telehealth prescribing cannot replicate physical examination. For GLP-1 therapy, relevant exam findings include abdominal tenderness (pancreatitis screening), neck palpation for thyroid nodules, and blood pressure measurement. Henry Meds, like most async telehealth platforms, relies entirely on patient self-report for these domains. The American Association of Clinical Endocrinology (AACE) 2023 obesity management guidelines recommend that prescribers conduct or have access to a comprehensive physical exam prior to initiating anti-obesity medications [7].

Henry Meds vs. Alternatives: A Clinical Comparison

Comparing Henry Meds to its main competitors on clinical infrastructure rather than price reveals meaningful differences.

vs. Ro (Body Program)

Ro requires a baseline lab panel and offers registered dietitian access as part of its weight program. The monthly price is higher (often $145, $299 for medication plus program fees, and labs are separate) but the structured follow-up is closer to a supervised care model.

vs. Hims & Hers

Hims offers compounded semaglutide at a similar price to Henry Meds and has faced the same FDA scrutiny on shortage-based compounding. Neither platform sets the standard for monitoring.

vs. HealthRX

HealthRX requires baseline labs, uses synchronous physician visits for initial prescribing, follows the STEP-1 titration schedule, and mandates a 12-week metabolic reassessment before prescription renewal. The price is higher. The clinical oversight is substantively different.

vs. Endocrinologist or obesity medicine specialist

An obesity medicine board-certified physician visit will cost $200, $500 out of pocket without insurance, plus the cost of branded medication. For patients with insurance coverage for Wegovy or Zepbound, this is the highest-evidence route. Patients without coverage face the same access problem that makes platforms like Henry Meds appealing in the first place.

The Compounded Tirzepatide Question

Tirzepatide (Zepbound for obesity, Mounjaro for type 2 diabetes) achieved 22.5% mean weight loss at 72 weeks in the SURMOUNT-1 trial (N=2,539) at the 15 mg dose [8]. That result is the strongest weight-loss efficacy signal from any pharmacologic intervention in the peer-reviewed literature to date.

Shortage status is different from semaglutide

As of early 2025, injectable tirzepatide remains on the FDA shortage list, meaning the legal basis for 503B compounding has not been removed. Henry Meds and similar platforms can still legally dispense compounded tirzepatide. The same quality and monitoring limitations described above apply, but the regulatory risk for supply disruption is lower in the near term compared to compounded semaglutide.

Efficacy extrapolation still does not hold

The 22.5% weight loss in SURMOUNT-1 used Eli Lilly's validated tirzepatide formulation. The trial ran 72 weeks with structured lab monitoring and 14 clinic visits [8]. A patient receiving compounded tirzepatide through an asynchronous platform is not receiving the same intervention that produced that result.

What Henry Meds Gets Right

A complete analysis requires acknowledging what the platform does well.

Access matters. For a patient with a BMI of 38 kg/m2, no insurance coverage for anti-obesity medication, and a household income that makes $1,300/month for Wegovy impossible, Henry Meds may represent the difference between receiving any therapy and receiving none. GLP-1 therapy at lower efficacy is better than no GLP-1 therapy for most patients in that group.

The prescribers are real. Licensed physicians or nurse practitioners review each case. This is not an over-the-counter supplement company or a gray-market peptide vendor.

The pharmacy network uses licensed facilities. 503A and 503B pharmacies are inspected by state boards and, for 503B, by the FDA. They are not clandestine operations.

Red Flags to Watch For as a Consumer

Patients considering Henry Meds or any compounded GLP-1 platform should watch for these specific warning signs.

No baseline labs required. If a platform will prescribe semaglutide or tirzepatide without any lab work, that is a gap from standard of care, full stop.

No synchronous visit option. Async-only prescribing for a drug with a boxed thyroid cancer warning is a structural limitation.

Vague pharmacy sourcing. The compounding pharmacy should be identifiable and have a 503A or 503B designation. "Our trusted pharmacy partners" without a named facility is not sufficient transparency.

No refill protocol tied to clinical reassessment. If refills are automatic without any check-in, the prescriber is not actively managing the patient, which is a departure from what the FDA's Risk Evaluation and Mitigation Strategy (REMS) framework expects of GLP-1 prescribers in high-risk subgroups [5].

Regulatory Trajectory and What Patients Should Plan For

The FDA's March 2024 removal of semaglutide from the shortage list was followed by a phased enforcement approach. The agency gave 503B outsourcing facilities until May 22, 2024 to stop bulk production, and 503A pharmacies until the same date to fill only patient-specific prescriptions rather than producing stock [1]. Enforcement activity against non-compliant facilities has been documented in FDA warning letters published in late 2024.

Patients currently receiving compounded semaglutide from Henry Meds face a non-trivial probability that their supply will be disrupted in 2025 if the platform's pharmacy network has not already transitioned. The FDA's stated position, as of the most recent guidance update, is that "compounded versions of semaglutide are not FDA-approved and do not have the same safety, efficacy, and quality assurances as FDA-approved drugs" [2].

Planning ahead means identifying a backup: either a manufacturer coupon program for branded semaglutide (Novo Nordisk's NovoCare program has helped patients access Ozempic for $99/month in some cases), a switch to tirzepatide while that shortage window remains open, or a transition to a platform with branded-drug prescribing capability.